MSD-ERTUGLIFLOZIN 15 ertugliflozin 15 mg film-coated tablet blister pack

Country: Ավստրալիա

language: անգլերեն

source: Department of Health (Therapeutic Goods Administration)

active_ingredient:

ertugliflozin pyroglutamic acid, Quantity: 19.43 mg (Equivalent: ertugliflozin, Qty 15 mg)

MAH:

Merck Sharp & Dohme (Australia) Pty Ltd

pharmaceutical_form:

Tablet, film coated

composition:

Excipient Ingredients: magnesium stearate; lactose monohydrate; sodium starch glycollate type A; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide red; macrogol 3350

administration_route:

Oral

units_in_package:

28, 7

prescription_type:

(S4) Prescription Only Medicine

therapeutic_indication:

MSD-ERTUGLIFLOZIN (ertugliflozin) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:- - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents,[see 5.1 PHARMACODYNAMIC PROPERTIES, Clinical trials and 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE for available data on different add-on combination therapies].

leaflet_short:

Visual Identification: Red, triangular-shaped, film-coated tablets debossed with '702' on one side and plain on the other side; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 2 Years; Container Temperature: Store below 30 degrees Celsius

authorization_status:

Licence status A

authorization_date:

2018-05-17